Marinus Pharmaceuticals Inc [NASDAQ: MRNS] plunged by -$1.39 during the normal trading session on while it closed the day at $0.30.
Marinus Pharmaceuticals Inc stock has also loss -82.99% of its value over the past 7 days. However, MRNS stock has declined by -79.30% in the 3 months of the year. Over the past six months meanwhile, it has lost -79.15% and lost -97.28% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for MRNS stock reached $16.30 million, with 54.58 million shares outstanding and 47.93 million shares in the current float. Compared to the average trading volume of 522.64K shares, MRNS reached a trading volume of 47639375 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Marinus Pharmaceuticals Inc [MRNS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNS shares is $3.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNS stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Marinus Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 23, 2024. The new note on the price target was released on August 14, 2024, representing the official price target for Marinus Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $20 to $2, while Robert W. Baird kept a Neutral rating on MRNS stock. On April 15, 2024, analysts decreased their price target for MRNS shares from 24 to 3.
The Average True Range (ATR) for Marinus Pharmaceuticals Inc is set at 0.21, with the Price to Sales ratio for MRNS stock in the period of the last 12 months amounting to 0.54.
MRNS stock trade performance evaluation
Marinus Pharmaceuticals Inc [MRNS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -82.99. With this latest performance, MRNS shares dropped by -82.99% in over the last four-week period, additionally sinking by -79.15% over the last 6 months – not to mention a drop of -95.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNS stock in for the last two-week period is set at 18.48, with the RSI for the last a single of trading hit 12.32, and the three-weeks RSI is set at 23.57 for Marinus Pharmaceuticals Inc [MRNS]. The present Moving Average for the last 50 days of trading for this stock 1.5501, while it was recorded at 1.4812 for the last single week of trading, and 4.0278 for the last 200 days.
Marinus Pharmaceuticals Inc [MRNS]: An insightful look at the core fundamentals
Marinus Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.15 and a Current Ratio set at 2.28.
Earnings per share (EPS) analysis for Marinus Pharmaceuticals Inc [MRNS] stock
With the latest financial reports released by the company, Marinus Pharmaceuticals Inc posted -0.61/share EPS, while the average EPS was predicted by analysts to be reported at -0.66/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Marinus Pharmaceuticals Inc go to 20.00%.
Marinus Pharmaceuticals Inc [MRNS]: Institutional Ownership
There are presently around $79.02%, or 79.78%% of MRNS stock, in the hands of institutional investors. The top three institutional holders of MRNS stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 4.8 million shares, which is approximately 8.443%. SOFINNOVA INVESTMENTS, INC., holding 4.15 million shares of the stock with an approximate value of $$4.86 million in MRNS stocks shares; and SOFINNOVA INVESTMENTS, INC., currently with $$4.66 million in MRNS stock with ownership which is approximately 7%.
